Table 1

Characteristics of 383 patients with SARS-CoV-2/COVID-19 by groups of BMI

CharacteristicsBMI, kg/m2P value
Underweight (n = 16, 4.2%)Normal (n = 203, 53.1%)Overweight (n = 123, 32.0%)Obesity (n = 41, 10.7%)
Age, years, median (IQR)35.5 (28–60)50 (36–62)50 (37–61)48 (39–54)0.13
Sex, females/males, n (% males)14/2 (12.5)127/76 (37.4)50/73 (59.4)9/32 (78.1)<0.001
Men, n (row %)2 (1.1)76 (41.5)73 (39.9)32 (17.5)
Women, n (row %)14 (7.0)127 (63.5)50 (25.0)9 (4.5)
Epidemiological information, n (%)
 From Hubei6 (37.5)118 (58.1)72 (58.5)19 (46.3)0.10
 Not been to Hubei, but infected by individuals from Hubei8 (50)72 (35.5)42 (34.2)14 (34.2)
 Without any clear contact history2 (12.5)13 (6.4)9 (7.3)8 (19.5)
Personal disease history, n (%)
 Diabetes
  No16 (100)192 (94.6)115 (93.5)38 (92.7)0.82
  Yes0 (0)11 (5.4)8 (6.5)3 (7.3)
 Hypertension
  No15 (93.8)174 (85.7)104 (84.6)32 (78.1)0.46
  Yes1 (6.3)29 (14.3)19 (15.5)9 (22)
 Cardiovascular disease
  No15 (93.8)185 (91.1)109 (88.6)39 (95.1)0.67
  Yes1 (6.3)18 (8.9)14 (11.4)2 (4.9)
 Liver disease
  No14 (87.5)196 (96.6)118 (95.9)35 (85.4)0.15
  Yes2 (12.5)7 (3.5)5 (4.1)6 (14.6)
 Cancer
  No16 (100)200 (98.5)122 (99.2)40 (97.6)0.72
  Yes0 (0)3 (1.5)1 (0.8)1 (2.4)
 COPD
  No14 (87.5)187 (92.1)112 (91.1)38 (92.7)0.86
  Yes2 (12.5)16 (7.9)11 (8.9)3 (7.3)
Initial symptoms, n (%)
 Fever
  No6 (37.5)64 (31.5)41 (33.3)5 (12.2)0.06
  Yes10 (62.5)139 (68.5)82 (66.7)36 (87.8)
 Cough
  No11 (68.8)135 (66.5)70 (56.9)18 (43.9)0.03
  Yes5 (31.3)68 (33.5)53 (43.1)23 (56.1)
 Fatigue
  No15 (93.8)192 (94.6)119 (96.8)41 (100)0.36
  Yes1 (6.3)11 (5.4)4 (3.3)0 (0)
 Headache
  No16 (100)198 (97.5)120 (97.6)41 (100)0.84
  Yes0 (0)5 (2.5)3 (2.4)0 (0)
 Diarrhea
  No16 (100)199 (98)120 (97.6)37 (90.2)0.09
  Yes0 (0)4 (2)3 (2.4)4 (9.8)
 Sore throat
  No16 (100)201 (99)121 (98.4)41 (100)0.81
  Yes0 (0)2 (1)2 (1.6)0 (0)
 Nasal congestion
  No16 (100)201 (99)121 (98.4)41 (100)0.81
  Yes0 (0)2 (1)2 (1.6)0 (0)
Disease progression, days, median (IQR)
 From onset to hospitalization4 (1–5)3 (2–6)4 (2–7)4 (2–6)0.52
 From onset to dyspnea8 (4–10)6.5 (3.5–8.5)8 (3–11)0.49
 From onset to ARDS9.5 (7–11)8 (6–10)7.5 (4–11.5)0.51
 From onset to manifestation as severe13 (10–21)13 (8–18)15.5 (10–20)0.74
 From onset to mechanical ventilation10 (7–15)9 (6.5–12.5)8 (4–12)0.88
 From onset to viral clearance of nasal swab14.5 (10–21)14 (9–18)15 (10–22)14 (9–20)0.14
 From onset to discharge25.5 (15–29.5)23 (17.5–31)27 (19–36)23.5 (19.5–32)0.17
Treatment, n (%)
 Lopinavir/ritonavir8 (50)148 (72.6)87 (70.7)30 (73.2)0.29
 Favipiravir2 (12.5)7 (3.4)5 (4.1)1 (2.4)0.32
 Need ICU care0 (0)16 (7.8)14 (11.4)5 (12.2)0.36
 Invasive mechanical ventilation0 (0)16 (7.8)14 (11.4)5 (12.2)0.36
 Extracorporeal membrane oxygenation0 (0)1 (0.5)1 (0.8)1 (2.4)0.62
Severity, n (%)
 Nonsevere16 (100)164 (80.8)87 (70.7)25 (61.0)0.001
 Severe0 (0)39 (19.2)36 (29.3)16 (39.0)
Death, n (%)
 No16 (100)202 (99.5)122 (99.2)40 (97.6)0.42
 Yes0 (0)1 (0.5)1 (0.8)1 (2.4)
  • ARDS, acute respiratory distress syndrome; ICU, intensive care unit.